Jin Medical International Ltd (ZJYL) Fair Value & Analysis
Healthcare · US · Market cap $19.3M
Fair value as of: Jun 26, 2026
Analysis
Jin Medical International Ltd (ZJYL) currently trades at $2.32, while our model-based Fair Value estimate is $2.97 — implying the stock looks roughly 28.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Jin Medical International Ltd. engages in the design, development, manufacture, and sale of wheelchair and other living aids for people with disabilities, the elderly, and people recovering from injury. The company offers wheelchairs and wheelchair components, such as wheels and brakes; oxygen concentrators, bath aids, and rehabilitative devices, as well as infrastructures for shared wheelchairs and other shared health products; oxygen chambers and beauty instruments; and shampoo instruments and nano thermal therapy chambers. It operates in the Mainland China, Japan, the United States, Hong Kong, Singapore, Korea, Australia, and internationally. The company was founded in 2006 and is based in Changzhou, China. Jin Medical International Ltd. operates as a subsidiary of Jolly Harmony Enterprises Limited.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Jin Medical International Ltd (ZJYL) undervalued?
What is the fair value of ZJYL?
What is the quality score of ZJYL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.